

Amendments to the Claims:

1 – 22. (Cancelled)

23. (Currently Amended) A method of preparing Use of an NspA protein of claim 10 in the preparation of a medicament containing an isolated, refolded NspA protein for treatment of prevention of Neisserial infection, said method comprising the steps of:

- a. optionally expressing an NspA protein in a host cell;
- b. optionally breaking the host cell to obtain an inclusion body comprising the NspA protein;
- c. optionally washing the inclusion body;
- d. optionally solubilizing at least part of the inclusion body and the NspA protein;
- e. contacting a solubilized NspA protein with a refolding buffer; and
- f. optionally removing the refolding buffer from the NspA protein.

24 – 34. (Cancelled)

35. (New) The method according to claim 23, wherein said refolding buffer comprises 3-dimethyldodecylammoniopropanesulfonate (SB-12).

36. (New) The method according to claim 35, wherein said refolding buffer additionally comprises ethanolamine.

37. (New) The method according to claim 36 wherein the ethanolamine is present at a concentration of about 20mM ethanolamine.

38. (New) The method according to claim 23 wherein the refolding buffer has pH 11.

39. (New) The method according to claim 23 wherein the SB-12 is 0.2% SB-12.

40. (New) The method according to claim 23 wherein the SB-12 is 0.5% SB-12.

41. (New) The method according to claim 23 wherein the SB-12 is purified.

42. (New) The method according to claim 41 wherein the SB-12 is purified by passing it over an Al₂O₃ column.
43. (New) A medicament prepared according to the method of claim 23.
44. (New) A medicament according to claim 43 wherein at least 50% of the NspA protein present in the composition is refolded.
45. (New) The method according to claim 23, wherein said refolded NspA protein is derived from *Neisseria meningitidis*.
46. (New) The method according to claim 23, wherein said refolded NspA protein is derived from *Neisseria gonorrhoeae*.
47. (New) The medicament according to claim 43 wherein said medicament comprises at least one other Neisserial antigen.
48. (New) The medicament according to claim 47 wherein said at least one other Neisserial antigen is selected from the group consisting of:
- a. at least one Neisserial adhesin selected from the group consisting of FhaB, Hsf, NadA, PilC, Hap, MafA, MafB, Omp26, NMB0315, NMB0995 and NMB1119;
 - b. at least one Neisserial autotransporter selected from the group consisting of Hsf, Hap, IgA protease, AspA and NadA;
 - c. at least one Neisserial toxin selected from the group consisting of FrpA, FrpC, FrpA/C, VapD, NM-ADPRT, and either or both of LPS immunotype L2 and LPS immunotype L3;
 - d. at least one Neisserial Fe acquisition protein selected from the group consisting of TbpA high, TbpA low, TbpB high, TbpB low, LbpA, LbpB, P2086, HpuA, HpuB, Lipo28, Sibp, FbpA, BfrA, BfrB, Bcp, NMB0964 and NMB0293; and
 - e. at least one Neisserial membrane associated protein, preferably outer membrane protein, selected from the group consisting of PldA, TspA, FhaC, TbpA(high), TbpA(low), LbpA, HpuB, TdfH, PorB, HimD, HisD, GNA1870, OstA, HlpA, MltA, NMB 1124, NMB 1162, NMB 1220, NMB 1313, NMB 1953, HtrA, TspB, PilQ and OMP85.

49. (New) The medicament of claim 43 further comprising one or more bacterial capsular polysaccharides or oligosaccharides.

50. (New) The medicament of claim 49 wherein said one or more capsular polysaccharides or oligosaccharides are derived from bacteria selected from the group consisting of *Neisseria meningitidis* serogroup A, C, Y, and/or W-135, *Haemophilus influenzae* b, *Streptococcus pneumoniae*, Group A Streptococci, Group B Streptococci, *Staphylococcus aureus* and *Staphylococcus epidermidis*, and are preferably conjugated to a source of T-helper epitopes.